XML 17 R7.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash flows from operating activities:    
Net loss $ (580) $ (26)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Net loss from securities transactions 237 258
Purchases of securities (942) (784)
Proceeds from sales of securities 993 660
Payments to cover securities sold, not yet purchased (626) (368)
Proceeds from securities sold, not yet purchased 94 100
Changes in receivables and payables relating to securities transactions 499 18
Changes in derivative assets and liabilities 156 (237)
Loss on disposition of assets, net 3 6
Depreciation and amortization 118 129
Impairment 10  
Deferred taxes (72) (16)
Other, net 79 12
Changes in other operating assets and liabilities (151) (3)
Net cash used by operating activities (182) (251)
Cash flows from investing activities:    
Capital expenditures (88) (68)
Turnaround expenditures (43) (12)
Proceeds from disposition of businesses and assets   2
Proceeds from sale of equity method investment 6  
Return of equity method investment 4 3
Other, net 3  
Net cash used in investing activities (118) (75)
Cash flows from financing activities:    
Investment segment distributions to non-controlling interests   (5)
Partnership contributions   50
Purchase of additional interests in consolidated subsidiaries (35)  
Dividends and distributions to non-controlling interests in subsidiaries (12) (28)
Proceeds from subsidiary borrowings   7
Repayments of subsidiary borrowings (13) (607)
Other, net (5) (4)
Net cash used in financing activities (65) (587)
Effect of exchange rate changes on cash and cash equivalents and restricted cash and restricted cash equivalents 1  
Net decrease in cash and cash equivalents and restricted cash and restricted cash equivalents (364) (913)
Cash and cash equivalents and restricted cash and restricted cash equivalents, beginning of period 5,239 5,946
Cash and cash equivalents and restricted cash and restricted cash equivalents, end of period $ 4,875 $ 5,033